Prospective Randomized Evaluation of Lymphaticovenous Anastomosis Using Dynamic Imaging in Breast Cancer-related Lymphoedema
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Royal Marsden NHS Foundation Trust
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- Mean excess volume reduction - compared between two cohorts
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Lymphoedema is a chronic debilitating disease that can have severe adverse effects on day-to-day life causing great physical and visual discomfort. The clinical presentation is characterised by chronic swelling of limbs, accompanied by localised pain, skin changes and recurrent infections. It is caused by a disruption in lymphatic flow which prevents the normal circulation of interstitial fluid (situated in the spaces between the cells of the body), resulting in swelling of the affected limb. It can be primary (cause unknown) or secondary to a number of causes such as malignancy, trauma, surgery, radiotherapy, infection, or venous disease.
In breast cancer treatment, axillary surgery and radiotherapy significantly damage normal lymphatic drainage of the upper limb, causing lymphoedema in 1-in-5 patients.
There is a growing body of evidence that this chronic and debilitating condition can be better managed through early surgical intervention rather than the current conservative management, which rely on pressure garments and massage. This surgical intervention, lymphaticovenous anastomosis (LVA), joins up a number of the draining lymphatic vessels to correspondingly sized veins on the affected limb using microsurgical techniques. A special dye and camera system is used to facilitate identifying lymph vessels. This creates a new drainage pathway for the lymph fluid around the area of disruption, improving lymphatic flow. Volume reduction is expected and this would be expected to provide quality of life benefits for the patients.
This study seeks to compare the outcomes from both therapies and determine whether LVA surgery can help to improve the physical burden and quality of life for patients affected by lymphoedema. Furthermore, lymphoedema places a substantial burden on NHS services. If this trial is successful, LVA surgery could improve patient outcomes and reduce the overall cost of treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Breast cancer patients treated with axillary surgery who have developed post-surgical lymphoedema (increase in limb volume by \>10% for 1 month or longer)
- •Patients must have completed their adjuvant therapy (excluding hormonal/long term Rx)
- •Patients must be within 6 months of having developed documented lymphoedema
Exclusion Criteria
- •• Contraindications to the use of the contrast agent (iodine allergy / untreated hypothyroidism)
- •Near infra-red spectroscopy providing insufficient data to guide surgery or evidence of LVA incompatibility (As these patients will be have only just developed lymphoedema, they are by definition very early in the spectrum of disease progression. Thus, the chances of all superficial lymphatics deteriorating to the extent that LVA surgery is not possible is extremely low - \<1% we expect).
- •Inability to give informed consent or cooperate with assessment procedures and follow-up because of cognitive or physical impairments
- •Medical co-morbidities increasing the risk of general anaesthetic (significant cardiac / respiratory disease)
- •Recurrent, metastatic or progressive disease, defined by oncology team on basis of clinical assessment or imaging
- •Evidence of pre-existing / primary lymphoedema on clinical history or lymphoscintigraphy
Outcomes
Primary Outcomes
Mean excess volume reduction - compared between two cohorts
Time Frame: 12 months from recruitment
Primary outcome measure is to evaluate the efficacy of LVA surgery (combined with CGT) by comparison of arm volume measurements across both the surgical and the control group at set time points post-surgery). This will be performed using the mean excess volume reduction (EVR) as a percentage change at 12 months - measured with perometry.
Secondary Outcomes
- Cellulitis(12 months from recruitment)
- Safety - infection and surgical complications(12 months from recruitment)
- Compliance(12 months from recruitment)
- Quality of life - LYMQOL score(12 months from recruitment)
- Bio-impedance spectroscopy(12 months from recruitment)